BRÈVE

sur Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Reports Continued Margin Improvement and Reduced Losses in Q1 FY 2025

Graphique de l'évolution du cours de l'action Biotricity, Inc. (EBR:BTCY).

Biotricity Inc. announced significant financial results for the first quarter of fiscal year 2025. The company showed substantial progress towards cash-flow break-even and profitability, driven by strong performance in its recurring technology fee revenue, which constitutes over 94% of total revenue with a 76% gross margin. The gross margins improved significantly to 73.8% from 63.5% in the same period last year.

Operating loss was reduced to $1.1 million, indicating efficiency gains of $1.2 million. Revenue grew by 6% year-over-year to $3.2 million. EBITDA and Adjusted EBITDA saw improvements of 18.9% and 49.8% respectively. Comprehensive loss was reported at $6.9 million due to one-time non-cash items, reducing the net loss to $3.7 million if excluded.

Dr. Waqaas Al-Siddiq, Founder & CEO, highlighted the company's focus on increasing sales of remote cardiac monitoring devices and subscription-based services. He emphasized the company's consistently strong gross margins and growth in recurring revenue as indicators of future profitability.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Biotricity, Inc.